Semaglutide peptides: the science behind the medicine, explained plainly

What makes semaglutide a peptide, and why that classification matters

The STEP 1 trial, published in the New England Journal of Medicine, demonstrated that semaglutide 2.4mg produced an average body-weight reduction of around 15% over 68 weeks in adults with obesity, a result that put GLP-1 receptor agonists firmly into mainstream medicine. Behind that result is a peptide: a molecule constructed from 31 amino acids, shaped to dock with the GLP-1 receptor as though it were the body's own glucagon-like peptide-1.

Peptides are simply short proteins. Your digestive system produces GLP-1 naturally after a meal; it signals fullness to the brain, slows the rate at which the stomach empties, and nudges insulin release. Natural GLP-1 breaks down within minutes. Semaglutide's designers lengthened its half-life dramatically (to around a week) by attaching a fatty-acid chain that binds to albumin in the blood, protecting it from rapid degradation. One weekly injection, one sustained signal. That engineering is the core of what makes Wegovy work.

The classification as a peptide is also why some people search for it alongside terms like "research peptides", and our semaglutide peptide page explains the chemistry and what that classification actually means in practice. The chemistry is the same word; the regulatory status is not. Anyone curious about what raw peptides semaglutide actually refers to, and how unprocessed versions differ from the licensed medicine, will find the distinction set out clearly there. A molecule called semaglutide that has not gone through pharmaceutical-grade manufacturing, clinical trial assessment and MHRA licensing is a different thing entirely in practice, whatever label it carries.

The gap between "peptides" sold online and the licensed medicine

Search for semaglutide peptides online and you will find suppliers (often based overseas) selling vials described as semaglutide for "research use only". The MHRA's position is straightforward: suspected illegal sellers can be reported via the Yellow Card scheme, and the regulator has repeatedly warned that medicines bought without a valid prescription from unverified sources carry serious risks. Purity, concentration and sterility cannot be confirmed. Some vials seized in enforcement actions have contained entirely different substances.

This is not a fine-print concern. Semaglutide is a Prescription-Only Medicine in the UK because its effects on appetite, heart rate, gastrointestinal function and blood-glucose regulation require a clinician to weigh up the risks against the benefits for the individual person in front of them. The peptide chemistry cannot do that weighing-up by itself.

If you want to understand how the licensed molecule compares across formulations, the semaglutide overview page covers the full picture, Wegovy injection, the newer oral tablet, and the diabetes medicine Ozempic, which contains the same active ingredient but holds a different licence. They are all semaglutide; they are not interchangeable.

Wegovy as the UK's licensed semaglutide for weight management

Wegovy is Novo Nordisk's brand of semaglutide approved in the UK specifically for weight management. The NHS medicines page for semaglutide sets out the patient-level information clearly: who it is for, how it is taken, what side effects to watch for. Adults with a BMI of 30 or above (or 27 or above alongside a weight-related condition such as high blood pressure or obstructive sleep apnoea) may be considered, subject to a full clinical assessment by a prescriber.

The treatment pathway matters as much as the molecule. Wegovy works alongside a reduced-calorie diet and increased activity; trials assessed it in that combined context, and the results reflect that. The most common side effects are gastrointestinal (nausea, loose stools, constipation, reflux) typically at their worst when a dose is first started or increased, then settling for most people within a couple of weeks. Serious effects, including pancreatitis, are rare but real, which is one reason prescriber oversight continues throughout treatment, not just at the start.

For a fuller comparison of how semaglutide sits alongside tirzepatide (Mounjaro) (the only dual GIP/GLP-1 agonist licensed in the UK) the Wegovy treatment page is a useful starting point, and semaglutide's role in weight loss covers the clinical evidence in more detail. Questions about whether Wegovy is technically a peptide in the research sense are answered on the is Wegovy a peptide page.

Getting semaglutide legally and safely in the UK

The only route to licensed semaglutide for weight management in the UK is a prescription. On the NHS, access sits within specialist weight management services under NICE guidance (TA875), and waiting times in many areas are long. Privately, a regulated online pharmacy can assess your suitability, issue a prescription and dispense, provided every step is done properly.

Checking that any online pharmacy is registered with the GPhC takes under a minute: the GPhC register is searchable by name or registration number. That check is worth doing before you hand over any personal or medical information. Our about us page explains how nume's clinical model works, including the fact that a GPhC-registered Independent Prescriber personally reviews every consultation the same day it is submitted, not a decision algorithm. Most people who order before noon on a working day have their treatment dispatched that afternoon and delivered the next working day in plain, unbranded packaging. It is the kind of thing that matters when you are waiting by the door before the school run.

If you would like to explore whether semaglutide or another licensed weight-loss treatment suits your situation, a look at the treatment options is a sensible first step. There is no obligation at that stage. For anything more specific (questions about your health history, current medicines or what the consultation involves) the team is reachable through our contact page any day of the week.